Our Mission: Highlighting Innovations by showcasing breakthroughs in cancer research, including diagnostic tools, therapies, and preventive measures.

AI & Technology in Cancer Care, Cellular Research, Clinical Research, Early Detection & Diagnostics, Global Trends, Personalized & Precision Medicine, Treatment Innovations

Arrivent Biopharma targets gastrointestinal cancer with new facility in Delaware County

Posted on

ArriVent Biopharma, a Delaware County-based company, has secured up to $150 million in Series A financing to advance its mission of bringing innovative cancer therapies to global markets. The initial $90 million investment was led by Hillhouse Capital Group, with additional support from Lilly Asia Ventures, OrbiMed, Octagon Capital Advisors, Boyu/Zoo Capital, and Lyra Capital. An additional $60 million is contingent upon achieving specific product development milestones.

In a strategic move, ArriVent has entered into a licensing agreement with Shanghai-based Allist Pharma, granting it rights to develop, manufacture, and commercialize furmonertinib outside of China. Furmonertinib has already received regulatory approval in China for treating locally advanced or metastatic non-small-cell lung cancer with specific genetic mutations. ArriVent plans to file an investigational new drug application with the U.S. Food and Drug Administration to further explore furmonertinib’s potential in treating non-small-cell lung cancer and other solid tumors.

Continue reading
Ovarian Cancer, Treatment Innovations, Early Detection & Diagnostics, Clinical Research, Cellular Research, Global Trends
ALONA MORANTA

Scientists find root cause of deadly ovarian cancer

Researchers have discovered the likely origin of a deadly form of ovarian cancer, offering new hope for early detection and better treatments.

Read More »
error: Content is protected !!